Ownership and insider activity for Design Therapeutics, Inc. (DSGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications.
Price
| Price | $12.31 |
| Market Cap | $769M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-09 | George Simeon | A-Award | 30,000 | $316K |
| 2026-06-09 | Schmid John P. | A-Award | 30,000 | $316K |
| 2026-06-09 | LAPPE RODNEY W | A-Award | 30,000 | $316K |
| 2026-06-09 | Gover Justin D. | A-Award | 30,000 | $316K |
| 2026-06-09 | Shapiro David | A-Award | 30,000 | $316K |
| 2026-06-09 | Berger Heather A. | A-Award | 30,000 | $316K |
| 2026-03-31 | Shapiro David | A-Award | 60,000 | $638K |
| 2026-03-31 | Shapiro David | A-Award | 7,500 | $80K |
| 2026-03-31 | Shapiro David | |||
| 2026-01-02 | Storgard Chris | A-Award | 250,000 | $2.3M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77000 | $2.4M | $298.6M | $26.5M | $21.2M | $22.6M | $16.9M |
| Short-term Investments | 0 | $33.7M | $85.5M | $303.9M | $260.6M | $222.9M | $203.0M |
| Receivables | 0 | $10000 | $110000 | $1.1M | $1.4M | $1.3M | $1.7M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $90000 | $36.2M | $385.4M | $335.1M | $284.6M | $248.0M | $223.8M |
| Property, Plant & Equipment | 0 | $71000 | $5.1M | $5.6M | $4.6M | $3.6M | $2.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $90000 | $36.5M | $390.6M | $341.1M | $289.6M | $252.1M | $226.2M |
| Accounts Payable | $2.5M | $1.4M | $1.6M | $3.0M | $1.9M | $2.2M | $2.3M |
| Short-term Debt | $695000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.7M | $2.3M | $5.3M | $10.8M | $9.6M | $8.5M | $13.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $645000 |
| Total Liabilities | $3.7M | $47.8M | $8.4M | $13.8M | $12.0M | $10.0M | $13.7M |
| Retained Earnings | -$3.6M | -$11.9M | -$47.5M | -$110.8M | -$177.6M | -$227.2M | -$297.0M |
| Total Equity | -$3.6M | -$11.3M | $382.1M | $327.3M | $277.7M | $242.1M | $212.5M |
| Total Debt | $695000 | 0 | $3.6M | $3.7M | $3.0M | $2.3M | $1.5M |
| Net Debt | $618000 | -$36.1M | -$380.4M | -$326.7M | -$278.7M | -$243.1M | -$218.3M |
| Working Capital | -$3.6M | $33.9M | $380.2M | $324.3M | $275.0M | $239.6M | $210.7M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 18.86 |
Profitability
| Return on Equity | -34.03% |
| Return on Invested Capital | -38.92% |
| Return on Assets | -32.91% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · AURA · DMAC · ENGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of DSGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks